Prostate cancer is the most commonly diagnosed noncutaneous cancer and second leading cause of cancer mortality in American men. The lifetime risk for prostate cancer is estimated at one in six; 30,000 men die of the disease annually in the US.
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Definition of Locally Advanced Prostate Cancer
LAPC has breached the prostatic capsule or invaded the seminal vesicles but has not spread to regional lymph nodes or metastatic sites (T3-4, N0-X, M0). These tumors are often bulky and most risk classification schemes (National Comprehensive Cancer Network, 3 Radiation Therapy Oncology
Group, 4 and D'Amico 5 ) place patients diagnosed with LAPC at high risk for disease recurrence, necessitating the need for aggressive therapeutic approaches up front to maximize the likelihood of a durable response or cure. Since extracapsular extension of the tumor often (not always-see Bonney 6 and Stephenson 7 for review of RP trials) makes these patients poor surgical candidates, the standard of care at most centers for men diagnosed with LAPC is high-dose conformal EBRT (>74 Gy 8 ) combined with ADT. For these patients, ADT is generally initiated 2-6 months prior to EBRT, given concurrently with EBRT, and continued in the adjuvant setting for a total of 2-3 years.
Origins of the Standard of Care for Locally Advanced Prostate Cancer
The standard of care for LAPC has been continuously refined with contributions from multiple randomized clinical trials over the last ~30 11 the EORTC 22961 trial, 12 and the TROG 03.04 trial 13 (see Table 1 ). These will be briefly reviewed here.
• EORTC 22863 9 enrolled 415 men with high grade or LAPC to determine the impact of ADT concurrent with and adjuvant to EBRT (70 Gy). p=0.0008) while improving event-free survival (aHR 0.51; p≤0.0001).
• EORTC 22961 12 is a follow up to EORTC 22863 and compared EBRT (70 Gy) supplemented with short-(6 months) or long-term (36 months) ADT with the hypothesis that short-term ADT would increase quality of life by decreasing ADT side effects while achieving therapeutic performance similar to long-term ADT. However, short-term ADT proved inferior to long-term ADT in terms of overall survival at 5 years and the study found no significant difference in overall quality of life.
• TROG 03. 24 Further, neoadjuvant ADT decreases local recurrence because it inhibits repopulation of the irradiated target area, 25 and improves long-term clinical outcomes because it is synergistic with EBRT. 9, 26 Several trials have likewise demonstrated a significant survival advantage is conferred by the use of ADT adjuvant to EBRT. 10, 12 However, the optimal duration of ADT in the adjuvant setting remains to be defined and likely varies based on tumor grade and patient characteristics.
Regardless, treating physicians must balance the clinical benefits of ADT with its side effects. While long-term adjuvant ADT appears necessary to maximize clinical benefit, there is a growing appreciation that its use is associated with increased morbidity.
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Recent Developments and Future Directions for Clinical Management of Locally Advanced Prostate Cancer
Irrespective of the agents used to accomplish castration, ADT carries a significant side-effect profile, including sexual dysfunction, hypogonadism, anemia, sarcopenia, cognitive dysfunction, increased risk for cardiovascular events, and metabolic dysfunction. 30, 32, 33 In an attempt to minimize these side effects, Nabid and colleagues compared EBRT combined with either 18 or 36 months of ADT. Six hundred and thirty men with high-grade (GS >7) T1c-T2a-b or T3-T4 tumors (N0-X, M0) were randomized to 18 or 36 months of ADT initiated 4 months prior to EBRT (70 Gy to the prostate;
44 Gy to pelvic lymph nodes). 34 The 10-year overall survival was 63.2 % in the 18-month ADT arm and 63.6 % in the 36-month ADT arm (p=0.429).
On the surface, these results seem to indicate ADT may be safely reduced from 36 to 18 months in patients diagnosed with LAPC. However, the study is yet to fully mature and several limitations must be considered when interpreting its results. 35 First, (75.4 %) of patients in this study had localized (T1c-T2a-b) high-grade tumors (GS >7) and 24.6 % of patients had T3-T4. This is in contrast to the reference study, EORTC 22863, where 89.6 % of tumors were T3-T4. Second, increased patient enrollment is required to generate the statistical power necessary to confidently conclude the two arms are equivalent in terms of overall survival. Therefore, while these results are suggestive that 18 months may be sufficient duration of ADT, the standard of care for locally advanced tumors (T3-T4) should remain 2-3 years of adjuvant ADT based on RTOG 92-02 and EORTC 22961
(discussed above).
While the optimal duration of adjuvant ADT in patients with LAPC may not be conclusively defined, three principles may be drawn from these trials: 1) ADT in combination with EBRT improves outcomes (all trials), 2) ADT prior to and concurrent with EBRT improves outcomes (RTOG 86-10, TROG 96.01), and 3) ADT concurrent and adjuvant to EBRT improves outcomes (EORTC 22863, EORTC 22961). However, the extrapolation of these principles into current practice is not clear-cut owing to widespread use of dose-escalated (>74 Gy) radiotherapy, 8 recent approval of second-generation androgen axis inhibitors, 36, 37 and the observation that neoadjuvant biochemical response predicts therapeutic outcomes. [21] [22] [23] To address these matters, the next generation of clinical trials must include ADT optimized to achieve maximal androgen suppression prior to the initiation of dose-escalated EBRT. For T2c-T4, N0, M0  T2b-T4, N0, patients treated with EBRT who had a serum PSA level >3 ng/ml more than 1 year after EBRT. These patients were randomized to CAD (696 patients, median survival 9.1 years) or IAD (690 patients, median survival 8.8 years). 38 Notably, there were no reported differences in adverse events between groups though the IAD arm reported improvement in several quality of life factors (fatigue, hot flashes, libido, etc.) In addition to minimizing the side effects associated with CAD, it is hypothesized that IAD may also delay the emergence of castration resistance by decreasing selective pressure against hormonally responsive tumor clonal populations. Unfortunately, time to hormone resistance could not be determined due to inherent bias in the study design, although it was likely similar between groups. 38 A recent meta-analysis of nine studies totaling 5,508 patients likewise failed to detect superiority of CAD over IAD in terms of clinical benefit, but did advocate use of IAD based on cost savings and decreased exposure to androgen deprivation in IAD cohorts, which resulted in decreased side effects. 39 Because ADT is not often prescribed for >36 months in patients with LAPC, the direct applicability of these trials to patients diagnosed with LAPC is uncertain. However, IAD represents a potential mechanism to minimize ADT-related toxicities and future trials in this area may ultimately prove useful in the treatment of LAPC.
Molecular Basis for Synergy of Androgen Deprivation Therapy with External Beam Radiation Therapy
Although In terms of clinical management, despite achieving castrate levels of serum testosterone (<0.5 ng/ml), conventional ADT results in a decrease of intraprostatic androgens by only ~75 %. 42, 43 Residual adrenal androgens 44 and de novo intratumoral androgen synthesis 45 effective when delivered after maximal tumor shrinkage in response to ADT, an effect that is almost completely lost if the tumor is allowed to re-grow in an androgen-independent manner following initial androgen ablation. [48] [49] [50] Many clinical trials are in line with these animal studies, reporting a biochemical response to neoadjuvant ADT independently predicts the survival benefit conferred by ADT with subsequent EBRT. [17] [18] [19] [20] [21] [22] [23] In addition, multivariate analysis in our trials 22, 23 revealed high-risk prostate cancer patients who achieved a pre-EBRT PSA of <0.5 ng/ ml (versus >0.5 ng/ml) after neoadjuvant ADT displayed longer time to distant metastatic spread and had improved failure-free, prostate cancer-specific, and overall survival at a median follow-up of 7 years. 22, 23 In sum, the clinical outcome of prostate cancer patients treated with ADT and EBRT may be closely linked to the efficacy of intratumoral androgen ablation and AR axis signaling suppression. In our experience, patients may be risk stratified as early as 3 months after initiation of ADT and those who fail to achieve a robust decrease in PSA are less likely to obtain the maximal therapeutic benefit that may be provided by the addition of EBRT. Encouragingly, both animal and clinical data support the molecular model that AR signaling supports resolution of DNA damage, highlighting an important new therapeutic angle in prostate cancer and also providing a rational explanation as to why prostate tumors treated with ADT often develop significant genomic instability. 40 In sum, active AR signaling primes cells for DNA repair and conventional ADT does not effectively abrogate AR signaling prior to EBRT initiation. Therefore, the use of potent second-generation agents in the neoadjuvant setting is expected to increase ADT-EBRT synergy, resulting in improved long-term outcomes.
Prognostic Biomarkers, Noninvasive Imaging to Diagnose and Monitor Prostate Cancer, and New Treatment Approaches
The majority of patients diagnosed with prostate cancer will die with, rather than of, the disease. The Gleason histopathologic grading system is commonly used to determine whether a tumor is likely to be aggressive (GS >8) and to guide subsequent therapy. 51 64, 65 Other approaches include the use of immuneactivating monoclonal antibodies (e.g. ipilimumab) 66 and the alpha emitter radium-223. 67 Last, the use of mouse avatar modeling systems, in which a patient-derived prostate tumor xenograft is implanted into a cohort of immunocompromised mice, which are then treated using various regiments in an effort to guide patient therapy in real time, is beginning to emerge in so-called co-clinical trials. Randomized clinical trials will provide valuable insight to guide therapy and allow physicians and patients to accurately weigh the significant side effect profile of ADT against its proven therapeutic benefits. n
